Gilead still at market perform by JMP

JMP Securities analyst Adam Cutler reiterated Gilead Sciences, Inc. at market perform. The company reported third-quarter non-GAAP earnings per share of $0.64, beating JMP's estimate of $0.53 and the Street consensus estimate of $0.56. Total revenues of $748.7 million also the analyst's estimate of $665.9 million and the Street expectation of $713.2 million. Shares of the Foster City, Calif.-based biopharmaceutical company were up 58 cents, or 0.86%, at $68.30. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.